MCT/LCT/omega-3 (5:4:1)
ApprovedSmall molecule
MCT/LCT/omega-3 (5:4:1) is one of 12 small molecule programs targeting Nosocomial Infection. It is currently in Approved.
1
Indications
1
Total Trials
0
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
15 competitors in Nosocomial Infection
#DrugCompanyPhaseTrials
1Cubicin
BBaxter Healthcare Corporation
Approved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Neupogen
EEastern Cooperative Oncology Group
Phase 3
MCT/LCT/omega-3 (5:4:1)
BB. Braun Medical Inc.
Approved
MCT/LCT
BB. Braun Medical Inc.
Approved
Talactoferrin
AAgennix
Phase 2
Chronulac
SSolvay Pharmaceuticals
Preclinical
Peridex
MMedline Industries
Preclinical
Merrem
BB. Braun Medical Inc.
Preclinical
Ceftazidime-Avibactam
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MCT/LCT/omega-3 (5:4:1). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- BB. Braun Medical Inc.